Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells

Acta Physiologica

Volumn 207, Issue 1, 2013, Pages 123-129

  Birder, L A ^a   Wolf Johnston, A S ^a   Sun, Y ^b   Chai, T C ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder urothelium; Capsaicin; Hypersensitivity; Muscarinic; Sensor function

Indexed keywords

ATROPINE METHYL NITRATE; CAPSAICIN; CAPSAZEPINE; MUSCARINIC M3 RECEPTOR; VANILLOID RECEPTOR 1;

ARTICLE; BLADDER UROTHELIAL CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; ADULT; CAPSAICIN; CHOLINERGIC AGONISTS; EPITHELIAL CELLS; HUMANS; MIDDLE AGED; PRIMARY CELL CULTURE; RECEPTOR, MUSCARINIC M3; SENSORY SYSTEM AGENTS; STIMULATION, CHEMICAL; TRPV CATION CHANNELS; URINARY BLADDER, OVERACTIVE; UROTHELIUM;

EID: 84870821092     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2012.02462.x     Document Type: Article

References (42)

1. Abrams, P., Andersson, K.E., Buccafusco, J.J., Chapple, C., de Groat, W.C., Fryer, A.D., Kay, G., Laties, A., Nathanson, N.M., Pasricha, P.J. & Wein, A.J. 2006. Muscarinic receptors: their distribution and function in body systems, and their implications for treating overactive bladder. Br J Pharmacol 148, 565-578.
2. Andersson, K.E., Gratzke, C. & Hedlund, P. 2010. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int 106, 1114-1127.
3. Apodaca, G., Balestreire, E. & Birder, L.A. 2007. The uroepithelial-associated sensory web. Kidney Int 72, 1057-1064.
4. Birder, L.A., Wolf-Johnston, A., Griffiths, D. & Resnick, N.M. 2007. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 26, 405-419.
5. Brady, C.M., Apostolidis, A.N., Harper, M., Yiangou, Y., Beckett, A., Jacques, T.S., Freeman, A., Scaravilli, F., Fowler, C.J. & Anand, P. 2004. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93, 770-776.
6. Burnstock, G. 2006. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58, 58-86.
7. Cruz, F. 2004. Mechanisms involved in new therapies for overactive bladder. Urology 63, 65-73.
8. Datta, S.N., Roosen, A., Pullen, A., Popat, R., Rosenbaum, T.P., Elneil, S., Dasgupta, P., Fowler, C.J. & Apostolidis, A. 2010. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration. J Urol 184, 2578-2585.
9. Dmitrieva, N. & McMahon, S.B. 1996. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66, 87-97.
10. Fowler, C.J. 2000. Intravesical treatment of overactive bladder. Urology 55, 60-64.
11. Gever, J.R., Soto, R., Henningsen, R.A., Martin, R.S., Hackos, D.H., Panicker, S., Rubas, W., Oglesby, I.B., Dillon, M.P., Milla, M.E., Burnstock, G. & Ford, A.P. 2010. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol 160, 1387-1398.
12. Gulur, D.M. & Drake, M.J. 2010. Management of overactive bladder. Nat Rev Urol 7, 572-582.
13. Gunthorpe, M.J. & Szallasi, A. 2008. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 14, 32-41.
14. Hanna-Mitchell, A.T., Beckel, J.M., Barbadora, S., Kanai, A.J., de Groat, W.C. & Birder, L.A. 2007. Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 80, 2298-2302.
15. Hegde, S.S. 2006. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147, S80-S87.
16. Kanai, A. & Andersson, K.-E. 2010. Bladder afferent signaling: recent findings. J Urol 183, 1288-1295.
17. Kim, Y., Yoshimura, N., Masuda, H., De Miguel, F. & Chancellor, M.B. 2006. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 97, 400-403.
18. Kissin, I. & Szallasi, A. 2011. Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials. Curr Top Med Chem 11, 2159-2170.
19. Koenig, J.A. & Edwardson, J.M. 1996. Intracellular trafficking of the muscarinic acetylcholine receptor: importance of subtype and cell type. J Pharmacol Exp Ther 49, 351-359.
20. Kullmann, F.A., Artim, D.E., Birder, L.A. & de Groat, W.C. 2008. Activation of muscarinic receptors in rat bladder sensry pathways alters reflex bladder activity. J Neurosci 28, 1977-1987.
21. Kuo, H.C., Liu, H.T., Guan, Z., Tyagi, P. & Chancellor, M.B. 2011. Promise of urinary nerve growth factor for assessment of overactive bladder syndrome. LUTS 3, 2-9.
22. Li, M., Sun, Y., Simard, J.M. & Chai, T.C. 2011. Increased transient receptor potential vanilloid type 1 (TRPV1) signaling in idiopathic overactive bladder urothelial cells. Neurourol Urodyn, 30, 606-611.
23. Liu, H.T. & Kuo, H.C. 2007. Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. BJU Int 100, 1086-1090.
24. Mansfield, K.J., Liu, L., Moore, K.H., Vaux, K.J., Millard, R.J. & Burcher, E. 2007. Molecular characterization of M2 and M3 muscarinic receptor expression in bladder from women with refractory idiopathic detrusor overactivity. BJU Int 99, 1433-1438.
25. Morrison, J. 1991. The activation of bladder wall afferents. Exp Physiol 84, 131-136.
26. Munoz, A., Somogyi, G.T., Boone, T.B. & Smith, C.P. 2011. Lumbosacral sensory neuronal activity is enhanced by activation of urothelial purinergic receptors. Brain Res Bull 86, 380-384.
27. Persson, P.B. 2012. Thoughts on publishing in physiology: a new chief editor takes on responsibility for Acta Physiologica (Oxford). Acta Physiol (Oxf) 204, 1-2.
28. Rapp, D.E., Lyon, M.B., Bales, G.T. & Cook, S.P. 2005. A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol 48, 303-308.
29. Round, P., Priestley, A. & Robinson, J. 2011. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Pharmacol 72, 921-931.
30. Ruggieri, M.R. 2006. Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction. Nat Clin Pract Urol 3, 206-216.
31. Schnegelsberg, B., Sun, T.T., Cain, G., Bhattacharya, A., Nunn, P.A., Ford, A.P., Vizzard, M.A. & Cockayne, D.A. 2010. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in bladder function. Am J Physiol 298, R534-R547.
32. Shieh, K.K., Yi, C.H., Tseng, H.L., Ho, H.C., Hsieh, H.T. & Chen, C.L. 2010. Evidence for neurotrophic factors associating with TRPV1 gene expression in the inflamed human intestine. Neurogastro Motil 22, 971-978.
33. Silva, C., Silva, J., Castro, H., Reis, F., Dinis, P., Avelino, A. & Cruz, F. 2007. Bladder sensory desensitization decreases urinary urgency. BMC Urol, 11, 7-9.
34. Tan, W., Contreras-Sanz, A., Kennedy-Lydon, T., Alexander, S.L., Janska, S., Bishara, S., Lunawat, R., Khasriya, R., Taylor, K.M., Crawford, C., Malone-Lee, J. & Wildman, S.S. 2009. Altered urothelial ATP signaling in human overactive (OAB) patients. Proc Physiol Soc 15, PC183.
35. Tyagi, P. 2011. Pathophysiology of the urothelium and detrusor. Can Urol Assoc J 5, S128-S130.
36. Wein, A.J. 2001. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 10, 65-83.
37. Yamaguchi, O. 2010. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 29, 112-115.
38. Yoshida, M., Inadome, A. & Maeda, Y. 2006. Non-neuronal cholinergic system in human bladder urothelium. Urology 67, 425-430.
39. Yoshida, M., Masunaga, K., Nagata, T., Yono, M. & Homma, Y. 2010. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharacotherapy of overactive bladder. J Pharmacol Sci 112, 128-134.
40. Yoshimura, N., Kaiho, Y., Miyazato, M., Yunoki, T., Tai, C., Chancelor, M.B. & Tyagi, P. 2007. Therapeutic receptor targets for lower urinary tract dysfunction. Naun Schmiedeberg's Arch Pharmacol 377, 437-448.
41. Zarghooni, S., Wunsch, J., Bodenbenner, M., Bruggmann, D., Grando, S.A., Schwantes, U., Wess, J., Kummer, W. & Lips, K.S. 2007. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci 80, 2308-2313.
42. Zhu, Y., Colak, T., Shenoy, M., Liu, L., Pai, R., Li, C., Mehta, K. & Pasricha, P.J. 2011. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastorenterol 141, 370-377.